Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3824218 | 0.88 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL470376 | 0.87 | PTGS2 (0.81) | PTGS2PTGS1 | |
| SCHEMBL3823978 | 0.86 | PTGS2 (0.76) | PTGS2PTGS1 | |
| SCHEMBL7215422 | 0.86 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL3823026 | 0.86 | PTGS2 (0.75) | PTGS2PTGS1 | |
| SCHEMBL3824407 | 0.86 | PTGS2 (0.75) | PTGS2PTGS1 | |
| SCHEMBL10092088 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL7210588 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL8504233 | 0.84 | PTGS2 (0.78) | PTGS2PTGS1 | |
| SCHEMBL3826907 | 0.84 | PTGS2 (0.77) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5935990-A | PYRROLYL DERIVATIVES HAVING AT POSITION 1 OR 5 A PHENYL SUBSTITUTED WITH METHYLSULFONYL OR AMINOSULFONYL; INHIBIT CYCLOOXYGENASE-2 FOR USE TREATMENT OF INFLAMMATION, AS AN ANALGESIC, OR AS AN ANTIPYRETIC | G.D. SEARLE & CO. (US) | 1999-08-10 | — | — | US | claimed |
| EP-0799823-B1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | DAIICHI SANKYO CO LTD (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-RE39420-E1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-12-05 | — | — | US | disclosed |
| CN-1151126-C | 1, 2-diphenylpyrrole derivatives, their preparation and their therapeutic uses | ������������ʽ���� | 2004-05-26 | — | — | CN | disclosed |
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-02-05 | — | — | US | disclosed |
| EP-1369415-A1 | Substituted pyrrolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2003-12-10 | — | — | EP | disclosed |
| US-6395724-B1 | COMPLEXES; ANTIINFLAMMATORY AGENTS; ANALGESICS; ANTIPYRETICS | ADVANCED MEDICINE, INC. | 2002-05-28 | — | — | US | disclosed |
| WO-1999063939-A9 | MULTIBINDING INHIBITORS OF CYCLOOXYGENASE-2 | ADVANCED MEDICINE INC (US) | 2001-04-12 | — | — | WO | disclosed |
| EP-1085845-A2 | MULTIBINDING INHIBITORS OF CYCLOOXYGENASE-2 | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-0989857-A4 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE INC (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-0989857-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | Advanced Medicine, Inc. (US) | 2000-04-05 | — | — | EP | disclosed |
| WO-1999063939-A2 | MULTIBINDING INHIBITORS OF CYCLOOXYGENASE-2 | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064037-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| EP-0946507-A1 | SUBSTITUTED PYRROLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1999-10-06 | — | — | EP | disclosed |
| US-5935990-A | PYRROLYL DERIVATIVES HAVING AT POSITION 1 OR 5 A PHENYL SUBSTITUTED WITH METHYLSULFONYL OR AMINOSULFONYL; INHIBIT CYCLOOXYGENASE-2 FOR USE TREATMENT OF INFLAMMATION, AS AN ANALGESIC, OR AS AN ANTIPYRETIC | G.D. SEARLE & CO. (US) | 1999-08-10 | — | — | US | disclosed |
| US-5908858-A | OSTEOPOROSIS; LEUKOTRIENE INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 1999-06-01 | — | — | US | disclosed |
| WO-1998025896-A1 | SUBSTITUTED PYRROLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-06-18 | — | — | WO | disclosed |
| CN-1168372-A | 1, 2-diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 1997-12-24 | — | — | CN | disclosed |
| EP-0799823-A1 | 1,2-Diphenylpyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1997-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | RNASE1, ENGASE, ENTPD5 | PTGS2 2939/4885PTGS1 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.